Vor Biopharma Inc Asset Resilience Ratio
Vor Biopharma Inc asset resilience ratio. Vor Biopharma Inc (VOR) has an Asset Resilience Ratio of 74.48% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See VOR defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Vor Biopharma Inc (2020–2025)
Asset resilience ratio of Vor Biopharma Inc from 2020 to 2025. This chart shows how Vor Biopharma Inc's Asset Resilience Ratio has changed over time. Read VOR liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Vor Biopharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Vor Biopharma Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $358.27 Million | 74.48% |
| Total Liquid Assets | $358.27 Million | 74.48% |
Asset Resilience Insights
- Very High Liquidity: Vor Biopharma Inc maintains exceptional liquid asset reserves at 74.48% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Vor Biopharma Inc Industry Peers by Asset Resilience Ratio
Compare Vor Biopharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Vor Biopharma Inc Asset Resilience Ratio by Year (2020–2025)
Vor Biopharma Inc asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Vor Biopharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.65% | $58.72 Million | $464.13 Million | +5.67pp |
| 2024-12-31 | 6.98% | $9.98 Million | $142.89 Million | -43.45pp |
| 2023-12-31 | 50.43% | $105.81 Million | $209.83 Million | -7.21pp |
| 2022-12-31 | 57.63% | $172.54 Million | $299.37 Million | +21.50pp |
| 2021-12-31 | 36.14% | $87.67 Million | $242.59 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $75.91 Million | -- |
About Vor Biopharma Inc
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with Re… Read more